Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhKGF-2 in ARDS
NCT07558538Phase 1Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- May 2026
- Primary completion
- Nov 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of repifermin in acute respiratory distress syndrome (ARDS) (6 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Adverse Events at Day 28, Serious Adverse Events at Day 28 and 4 more. Started May 2026; status: recruiting.
02
Drugs
repifermin
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT07558538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07558538.